Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Melissa E. Hogg, Amir A. Borhani, Herbert J. Zeh, Juliana Tobler, Ahmad Hamad, Mazen S. Zenati, Amer H. Zureikat, Patrick R. Varley, A. Klobuka
Publikováno v:
HPB. 21:695-701
We sought to investigate whether robotic pancreatoduodenectomy (RPD) mitigates adverse outcomes in patients with high-risk morphometric features compared to the open approach (OPD).Morphometric parameters for RPD and OPDs were measured by two blinded
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Matthew P. Holtzman, Melissa E. Hogg, J. Wallis Marsh, David L. Bartlett, James F. Pingpank, Mashaal Dhir, Amer H. Zureikat, David A. Geller, M. Haroon A. Choudry, Herbert J. Zeh, Heather L. Jones, Mazen S. Zenati, Nathan Bahary, Allan Tsung
Publikováno v:
Annals of Surgical Oncology. 25:550-557
In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver me
Autor:
Pranav Murthy, Amr I. Al Abbas, Mazen S. Zenati, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat, Brian A. Boone, Caroline J. Rieser, Herbert J. Zeh
Publikováno v:
Ann Surg Oncol
BACKGROUND. The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed a
Publikováno v:
Annals of surgical oncology. 25(7)
National adherence to treatment guidelines for pancreatic ductal adenocarcinoma (PDAC) is a concern. This study aims to evaluate national expected treatment (ET) adherence for all PDAC stages. We hypothesized that both patient and hospital demographi
Autor:
Nathan Bahary, Ahmad Hamad, Herbert J. Zeh, Mazen S. Zenati, Amer H. Zureikat, Mashaal Dhir, Aatur D. Singhi, Melissa E. Hogg
Publikováno v:
Annals of surgical oncology. 25(7)
Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA). This study aimed to compare neoadjuvant FOLFIRINOX and G-nP in the treatment of resectable (R) a
Autor:
Ahmad Hamad, Melissa E. Hogg, Caroline J. Rieser, Amr I. Al Abbas, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 25(12)
Serum carbohydrate antigen 19-9 (CA19-9) correlates with response to therapy and overall survival (OS) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to define the chronologic relationship between CA19-9 elevation and rad
Autor:
Nathan Bahary, Jennifer Steve, Herbert J. Zeh, David L. Bartlett, Amer H. Zureikat, Brian A. Boone, Melissa E. Hogg, Mazen S. Zenati, Aatur D. Singhi
Publikováno v:
Annals of Surgical Oncology. 21:4351-4358
Baseline carbohydrate antigen 19-9 (CA 19-9) is a useful prognostic marker in pancreatic ductal adenocarcinoma (PDA); however, data on the significance of a change in CA 19-9 following neoadjuvant therapy are lacking.All patients receiving neoadjuvan
Autor:
Ahmad Hamad, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Jennifer Steve, Kenneth K. Lee, Irene Epelboym, Melissa E. Hogg, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 24(9)
Receipt of 6 cycles of adjuvant chemotherapy (AC) is standard of care in pancreatic cancer (PC). Neoadjuvant chemotherapy (NAC) is increasingly utilized; however, optimal number of cycles needed alone or in combination with AC remains unknown. We sou